Laboratory Company Top Insiders
LH Stock | USD 243.04 0.68 0.28% |
Laboratory employs about 60.9 K people. The company is managed by 36 executives with a total tenure of roughly 175 years, averaging almost 4.0 years of service per executive, having 1691.67 employees per reported executive. Assessment of Laboratory's management performance can provide insight into the firm performance.
Adam Schechter Chairman Chairman of the Board, President, Chief Executive Officer |
Glenn Eisenberg President Chief Financial Officer, Executive Vice President |
Laboratory | Build AI portfolio with Laboratory Stock |
Laboratory's latest congressional trading
Congressional trading in companies like Laboratory, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Laboratory by those in governmental positions are based on the same information available to the general public.
2025-07-10 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
2025-05-08 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
2025-04-08 | Representative Gilbert Cisneros | Acquired Under $15K | Verify | ||
2025-03-28 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
2025-03-21 | Representative John Delaney | Acquired Under $15K | Verify | ||
2023-09-22 | Senator Dan Sullivan | Acquired Under $15K | Verify | ||
2023-09-17 | Senator Dan Sullivan | Acquired Under $15K | Verify | ||
2020-08-12 | Senator James Inhofe | Acquired $50K to $100K | Verify | ||
2019-05-03 | Senator James Inhofe | Acquired $50K to $100K | Verify |
Laboratory Management Team Effectiveness
The company has Return on Asset (ROA) of 0.0418 % which means that for every $100 of assets, it generated a profit of $0.0418. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0898 %, which means that it produced $0.0898 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities.Laboratory Workforce Comparison
Laboratory of is rated third overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 295,543. Laboratory totals roughly 60,900 in number of employees claiming about 21% of equities under Health Care industry.
The company has Net Profit Margin (PM) of 0.06 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.1 %, which signifies that for every $100 of sales, it has a net operating income of $0.1. Laboratory Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Laboratory insiders, such as employees or executives, is commonly permitted as long as it does not rely on Laboratory's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Laboratory insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kerrii Anderson over two weeks ago Disposition of 500 shares by Kerrii Anderson of Laboratory at 265.0 subject to Rule 16b-3 | ||
Van Der Vaart Sandra D over two months ago Disposition of 323 shares by Van Der Vaart Sandra D of Laboratory subject to Rule 16b-3 | ||
Akinbolade Oyegunwa over six months ago Acquisition by Akinbolade Oyegunwa of 1110 shares of Laboratory subject to Rule 16b-3 | ||
Glenn Eisenberg over six months ago Disposition of 9071 shares by Glenn Eisenberg of Laboratory at 224.5488 subject to Rule 16b-3 | ||
Peter Wilkinson over a year ago Disposition of 894 shares by Peter Wilkinson of Laboratory at 216.57 subject to Rule 16b-3 | ||
Glenn Eisenberg over a year ago Disposition of 18379 shares by Glenn Eisenberg of Laboratory at 215.3661 subject to Rule 16b-3 | ||
Rothman Paul over a year ago Acquisition by Rothman Paul of 717 shares of Laboratory subject to Rule 16b-3 | ||
Lance Berberian over a year ago Disposition of 3299 shares by Lance Berberian of Laboratory at 216.57 subject to Rule 16b-3 |
Laboratory Notable Stakeholders
A Laboratory stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Laboratory often face trade-offs trying to please all of them. Laboratory's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Laboratory's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Paul Kirchgraber | Executive Vice President and Chief Executive Officer - Covance Drug Development | Profile | |
Adam Schechter | Chairman of the Board, President, Chief Executive Officer | Profile | |
Glenn Eisenberg | Chief Financial Officer, Executive Vice President | Profile | |
Lance Berberian | Executive Vice President, Chief Technology Officer, Chief Information Officer | Profile | |
JD MD | President EVP | Profile | |
Peter Wilkinson | Senior Vice President, Chief Accounting Officer | Profile | |
Brian Caveney | Executive Vice President, President, Diagnostics and Chief Medical Officer | Profile | |
Sandra Vaart | Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | Profile | |
Julia Wang | CFO VP | Profile | |
Kerrii Anderson | Independent Director | Profile | |
JeanLuc Belingard | Independent Director | Profile | |
Peter Neupert | Lead Independent Director | Profile | |
Richelle Parham | Independent Director | Profile | |
Robert Williams | Independent Director | Profile | |
Jeffrey Davis | Independent Director | Profile | |
Garheng Kong | Independent Director | Profile | |
Marcia Eisenberg | Enterprise VP | Profile | |
Sandra JD | Chief VP | Profile | |
Deborah SesokPizzini | SVP Officer | Profile | |
Akinbolade Oyegunwa | Executive Officer | Profile | |
Anita Graham | Executive Officer | Profile | |
Judith Seltz | Chief Human Resource Officer, Executive Vice President | Profile | |
Michelle Abelson | Laboratory Operations | Profile | |
Jonathan DiVincenzo | Executive International | Profile | |
Amy Summy | Executive Vice President Chief Marketing Officer | Profile | |
Mark Schroeder | Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | Profile | |
Robert Pringle | Senior Treasurer | Profile | |
Paul MD | Ex Devel | Profile | |
John Treadwell | Vice Initiatives | Profile | |
D Gilliland | Independent Director | Profile | |
Akinbolade MBA | Executive Officer | Profile | |
Kathryn Wengel | Independent Director | Profile | |
Christin ODonnell | Vice Relations | Profile | |
Megan MPH | Executive Officer | Profile | |
Chas Cook | VP Relations | Profile | |
MPH MD | Pres VP | Profile |
About Laboratory Management Performance
The success or failure of an entity such as Laboratory often depends on how effective the management is. Laboratory management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Laboratory management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Laboratory management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina. Laboratory Corp operates under Diagnostics Research classification in the United States and is traded on New York Stock Exchange. It employs 75000 people.
Laboratory Workforce Analysis
Traditionally, organizations such as Laboratory use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Laboratory within its industry.Laboratory Manpower Efficiency
Return on Laboratory Manpower
Revenue Per Employee | 213.6K | |
Revenue Per Executive | 361.4M | |
Net Income Per Employee | 12.2K | |
Net Income Per Executive | 20.7M | |
Working Capital Per Employee | 24.2K | |
Working Capital Per Executive | 41M |
Complementary Tools for Laboratory Stock analysis
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |